ArticleBiosafety and health2019
SINS model in the management of biosafety level 2 laboratories: exploration and practice.
Article in Biosafety and health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy.Clinical reviews in allergy & immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significant number of biosafety level 2 (BSL-2) laboratories have been established in many countries for studies of various types of pathogenic agents and other infectious biological materials. The harmonized management of biological risks in such diverse laboratories thus appears as a real challenge. Zhejiang Province in China has taken the initiative to establish a comprehensively integrated laboratory biosafety management system called SINS (Standardization, Informatization, Normalization and Systematization). The SINS model system has been introduced and adopted in 1,721 BSL-2 laboratories in Zhejiang Province, and thus lead to an increase in the number of biosafety committees from 20% to more than 95% from 2007 to 2018, and the number of biosafety laboratory managers who knows biosafety-related laws and regulations increase from 52.7% to 83.7% from 2009 to 2017. Such achievements indicate that the successful implementation of SINS model has increased the effective control of biological risks in BSL-2 laboratories of the Zhejiang Province. SINS model and its main effects on leading the improvement of laboratory biosafety management was presented in this review. The SINS model helps to strengthen laboratory biosafety and thus effectively reduces occurrence of biosafety-related incidences. This model can potentially be used by other regions or countries where harmonized biosafety management system is still under-developing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.